The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value

Taylor and Francis Group, Acta Clinica Belgica, 1(78), p. 78-86, 2022

Journal article published in 2022 by Esther Janssens

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by